arrow_back Back to App

New Medicare Drug Guidelines: Better Adherence and Cheaper Alternatives.

This new bill aims to improve how patients take their Medicare Part B and D drugs. This means citizens can better manage their health and gain easier access to more affordable generic and biosimilar drugs, potentially lowering their treatment costs.
Key points
Establishment of guidelines to achieve 90% adherence for Medicare Part B and D drugs.
Incorporation of artificial intelligence to improve drug adherence.
Promotion of generic and biosimilar drugs to reduce costs for patients.
article Official text account_balance Process page
Introduced
Citizen Poll
No votes cast
Additional Information
Print number: 119_HR_1142
Sponsor: Rep. Schweikert, David [R-AZ-1]
Process start date: 2025-02-07
Lustra uses Artificial Intelligence. Verify details in source documents.
Summarized by: gemini-2.5-flash
Source data: api.congress.gov
AI work logs for this document launch

OFFICIAL LEGAL TITLE

To amend the Public Health Service Act to direct the Secretary of Health and Human Services to establish drug adherence guidelines, and for other purposes.

FREQUENTLY ASKED QUESTIONS

What is the official ID of this bill?

The official print number for this legislation is 119_HR_1142.

Which chamber initiated this legislation?

This legislation was initiated in the House of Representatives.

When did the legislative process begin?

The process officially started on 2025-02-07.

What are the main provisions?

Key points include:

  • Establishment of guidelines to achieve 90% adherence for Medicare Part B and D drugs.
  • Incorporation of artificial intelligence to improve drug adherence.
  • Promotion of generic and biosimilar drugs to reduce costs for patients.
What is the specific legal status?

The current status is Introduced.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Rep. Schweikert, David [R-AZ-1].

What is the latest detailed status?

The latest detailed status is: Referred to the House Committee on Energy and Commerce.

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-22.

CATEGORIES

Health